DETAILED ACTION
Status of Claims
Claims 1-11 are currently pending. Claims 1-11 are currently under consideration and are the subject of this Office Action. This is the first Office Action on the merits of the claims. Non-elected claims 12-20 are withdrawn from consideration. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of Office Action: Non-Final.
Election/Restrictions
Applicant’s election of the claims of Group I (claims 1-11) in the response filed on August 10, 2026 (to the April 15, 2026 Requirement for Restriction) is acknowledged. In response to applicant’s election, the claims of Group II (claims 12-20) is withdrawn from further consideration pursuant to 37 C.F.R. § 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant has elected the claims of Group I without traverse.
Also in the response dated August 10, 2026, applicant elected, {with/without} traverse, the following species:
(i) Chitosan microparticles containing
a. cisplatin as the therapeutic agent, and
b. sodium tripolyphosphate; and
(ii) Further components which are:
a. Propylene glycol as the hydration promoter,
b. HPMC as the microparticle adhesion inhibitor,
c. Sucralose as the microparticle aggregation inhibitor, and
d. cisplatin as a free therapeutic agent in the matrix.
and identified claims 1-11 as reading on the elected species.
Accordingly, the April 15, 2026 Requirement for Restriction is made FINAL, and claims 1-11 are examined as follows.
Claim Objections
The following claims are objected to because of the following informalities: Claim 2 is objected to because the claim should read:
2. (Original) A system according to claim 1, wherein the composition further includes a compound selected from a group consisting of a hydration promoter, a microparticle adhesion inhibitor comprising hydroxypropylmethylcellulose (HPMC), a microparticle aggregation inhibitor, and combinations thereof.
Appropriate correction is required.
Claim Rejections - Nonstatutory Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.
Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).
Claims 1-11 are rejected on the ground of nonstatutory double patenting over claims 1-10 of US 10,398,655 B2 to GOLDBERG to Goldberg et al., hereinafter “‘655 Patent,” matured from copending Application No. 15/436,651.
Although the conflicting claims are not identical, they are not patentably distinct because the instant claims as well as the co-pending claims are drawn to a system for delivery of a therapeutic agent comprising a matrix having a first and second opposed surfaces, wherein the matrix is formed by chitosan and a plurality of microparticles.
Claim 1 is anticipated by claim 1 of the ‘655 Patent.
Claim 2 is anticipated by claim 1 of the ‘655 Patent.
Claim 3 is anticipated by claim 2 of the ‘655 Patent.
Claim 4 is anticipated by claim 3 of the ‘655 Patent.
Claim 5 is anticipated by claim 4 of the ‘655 Patent.
Claim 6 is anticipated by claim 5 of the ‘655 Patent.
Claim 7 is anticipated by claim 6 of the ‘655 Patent.
Claim 8 is anticipated by claim 7 of the ‘655 Patent.
Claim 9 is anticipated by claim 8 of the ‘655 Patent.
Claim 10 is anticipated by claim 9 of the ‘655 Patent.
Claim 11 is anticipated by claim 10 of the ‘655 Patent.
Claims 1-11 are rejected on the ground of nonstatutory double patenting over claims 1-5 and 7-9 of US 10,478,403 B1 to GOLDBERG to Goldberg et al., hereinafter “‘403 Patent,” matured from copending Application No. 15/970,513.
Although the conflicting claims are not identical, they are not patentably distinct because the instant claims as well as the co-pending claims are drawn to a system for delivery of a therapeutic agent comprising a matrix having a first and second opposed surfaces, wherein the matrix is formed by chitosan and a plurality of microparticles.
Claim 1 is anticipated by claim 1 of the ‘403 Patent.
Claim 2 is anticipated by claim 1 of the ‘403 Patent.
Claim 3 is anticipated by claim 2 of the ‘403 Patent.
Claim 4 is anticipated by claim 3 of the ‘403 Patent.
Claim 5 is anticipated by claim 4 of the ‘403 Patent.
Claim 6 is anticipated by claim 5 of the ‘403 Patent.
Claim 7 is anticipated by claim 1 of the ‘403 Patent.
Claim 8 is anticipated by claim 7 of the ‘403 Patent.
Claim 9 is anticipated by claim 1 of the ‘403 Patent.
Claim 10 is anticipated by claims 8-9 of the ‘403 Patent.
Claim 11 is anticipated by claim 1 of the ‘403 Patent.
Claims 1-11 are rejected on the ground of nonstatutory double patenting over claims 1-10 of US 11,617,722 B2 to GOLDBERG to Goldberg et al., hereinafter “‘722 Patent,” matured from copending Application No. 16/557,599.
Although the conflicting claims are not identical, they are not patentably distinct because the instant claims as well as the co-pending claims are drawn to a system for delivery of a therapeutic agent comprising a matrix having a first and second opposed surfaces, wherein the matrix is formed by chitosan and a plurality of microparticles.
Claim 1 is anticipated by claim 1 of the ‘722 Patent.
Claim 2 is anticipated by claim 1 of the ‘722 Patent.
Claim 3 is anticipated by claim 2 of the ‘722 Patent.
Claim 4 is anticipated by claim 3 of the ‘722 Patent.
Claim 5 is anticipated by claim 4 of the ‘722 Patent.
Claim 6 is anticipated by claim 5 of the ‘722 Patent.
Claim 7 is anticipated by claim 6 of the ‘722 Patent.
Claim 8 is anticipated by claim 7 of the ‘722 Patent.
Claim 9 is anticipated by claim 8 of the ‘722 Patent.
Claim 10 is anticipated by claim 9 of the ‘722 Patent.
Claim 11 is anticipated by claim 10 of the ‘722 Patent.
Claims 1-11 are rejected on the ground of nonstatutory double patenting over claims 1-5 and 7-8 of US 11,872,319 B2 to GOLDBERG to Goldberg et al., hereinafter “‘319 Patent,” matured from copending Application No. 16/679,764.
Although the conflicting claims are not identical, they are not patentably distinct because the instant claims as well as the co-pending claims are drawn to a system for delivery of a therapeutic agent comprising a matrix having a first and second opposed surfaces, wherein the matrix is formed by chitosan and a plurality of microparticles.
Claim 1 is anticipated by claim 1 of the ‘319 Patent.
Claim 2 is anticipated by claim 1 of the ‘319 Patent.
Claim 3 is anticipated by claim 2 of the ‘319 Patent.
Claim 4 is anticipated by claim 3 of the ‘319 Patent.
Claim 5 is anticipated by claim 4 of the ‘319 Patent.
Claim 6 is anticipated by claim 5 of the ‘319 Patent.
Claim 7 is anticipated by claim 1 of the ‘319 Patent.
Claim 8 is anticipated by claim 7 of the ‘319 Patent.
Claim 9 is anticipated by claim 1 of the ‘319 Patent.
Claim 10 is anticipated by claim 8 of the ‘319 Patent.
Claim 11 is anticipated by claim 1 of the ‘319 Patent.
Claims 1-7, 9 and 11 are rejected on the ground of nonstatutory double patenting over claims 1, 3-4 and 6 of US 11,938,228 B2 to Goldberg et al., hereinafter “‘228 Patent,” matured from copending Application No. 16/241,408.
Although the conflicting claims are not identical, they are not patentably distinct because the instant claims as well as the co-pending claims are drawn to a system for delivery of a therapeutic agent comprising a matrix having a first and second opposed surfaces, wherein the matrix is formed by chitosan and a plurality of microparticles.
Claim 1 is anticipated by claim 1 of the ‘228 Patent.
Claim 2 is anticipated by claim 1 of the ‘228 Patent.
Claim 3 is anticipated by claim 3 of the ‘228 Patent.
Claim 4 is anticipated by claim 1 of the ‘228 Patent.
Claim 5 is anticipated by claim 1 of the ‘228 Patent.
Claim 6 is anticipated by claim 1 of the ‘228 Patent.
Claim 7 is anticipated by claims 3-4 of the ‘228 Patent.
Claim 9 is anticipated by claim 6 of the ‘228 Patent.
Claim 11 is anticipated by claim 6 of the ‘228 Patent.
Claims 1-7 and 9-11 are rejected on the ground of nonstatutory double patenting over claims 1, 8, 11, 13,16 and 19 of US 12,589,080 B2 to Goldberg et al., hereinafter “‘080 Patent,” matured from copending Application No. 17/830,078.
Although the conflicting claims are not identical, they are not patentably distinct because the instant claims as well as the co-pending claims are drawn to a system for delivery of a therapeutic agent comprising a matrix having a first and second opposed surfaces, wherein the matrix is formed by chitosan and a plurality of microparticles.
Claim 1 is anticipated by claim 1 of the ‘080 Patent.
Claim 2 is anticipated by claim 11 of the ‘080 Patent.
Claim 3 is anticipated by claim 8 of the ‘080 Patent.
Claim 4 is anticipated by claim 13 of the ‘080 Patent.
Claim 5 is anticipated by claim 19 of the ‘080 Patent.
Claim 6 is anticipated by claim 16 of the ‘080 Patent.
Claim 7 is anticipated by claim 1 of the ‘080 Patent.
Claim 9 is anticipated by claim 1 of the ‘080 Patent.
Claim 10 is anticipated by claim 1 of the ‘080 Patent.
Claim 11 is anticipated by claim 7 of the ‘080 Patent.
Allowable Subject Matter
Claims 1-11 are drawn to allowable material pursuant to filing terminal disclaimers for the double patenting references indicated above. US 2014/0234212 A1 by Goldberg et al. is noted as a reference of interest as to the closest prior art. To the extent that claims 12-20 could be rejoined, US 10,159,651 (matured from US Appl. No. 15/897,729) would be a reference of interest as to double patenting, and in this respect, claim 12 should be amended to recite “[a] method for manufacturing a therapeutic agent delivery system according to claim 1,” in order to also encompass (i) and (ii) of claim 1.
.
Conclusion
Claims 1-11 are rejected. No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to DOMINIC LAZARO whose telephone number is (571)272-2845. The examiner can normally be reached on Monday through Friday, 8:30am to 5:00pm EST; alternating Fridays out.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, BETHANY BARHAM can be reached on (571)272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/DOMINIC LAZARO/Primary Examiner, Art Unit 1611